Squarepoint’s Dimension Therapeutics, Inc DMTX Stock Holding History

Squarepoint’s Portfolio DMTX Stock Details DMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-24,370	Closed	-$106K	–	2223
2016 Q4	$106K	Buy	+24,370	New	+$130K	﹤0.01%	1614

Other funds holding DMTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Squarepoint's DMTX Position: Q1 2017 in Review

Squarepoint sold out of Dimension Therapeutics, Inc (DMTX) in Q1 2017, closing a stake of 24,370 shares — an estimated $106K sold.

Squarepoint first reported a position in DMTX in Q4 2016 and held it in 1 quarter. The position peaked at $106K in Q4 2016. 47 funds tracked by Wall St. Rank hold DMTX as of Q1 2017.

Squarepoint reported no remaining Dimension Therapeutics, Inc position as of Q1 2017 after selling out during the quarter.
Squarepoint sold 24,370 Dimension Therapeutics, Inc shares in Q1 2017, an estimated $106K.
Squarepoint first reported a position in Dimension Therapeutics, Inc in Q4 2016 and held it in 1 quarter.
Squarepoint's Dimension Therapeutics, Inc position peaked at $106K in Q4 2016.
47 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q1 2017.

Based on Squarepoint's 13F filing for Q1 2017, filed 15 May 2017.